Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on MeiraGTx (MGTX) to $30 from $28 and keeps an Overweight rating on the ...

Eli Lilly and Company is positioned for substantial growth following significant regulatory and strategic developments.

WASHINGTON-Syria has joined the U.S.-led mission to defeat Islamic State, U.S. officials said, after President Trump and Syrian President Ahmed al-Sharaa met at the White House on Monday. The move ...

MeiraGTx Holdings PLC stock grades by Barron's. View MGTX fundamental and sentiment analysis powered by MarketGrader.

Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the ...

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to ...

Lilly gains worldwide exclusive rights to MeiraGTx AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4.

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to ...

MeiraGTx will receive an upfront payment of $75 million and will be eligible to receive over $400 million in total milestone ...

The drugmaker is paying MeiraGTx $75 million upfront and $400 million in milestone payments to gain access to a treatment for LCA4 caused by AIPL1 mutations.

US clinical-stage genetic medicines company MeiraGTx Holdings saw its shares rise 15% to $9.74 pre-market today, as it ...